Vertex Pharmaceuticals Incorporated (VRTX)

NASDAQ: VRTX · Real-Time Price · USD

535.17

+10.65 (2.03%)

At close: Oct 22, 2026, 4:00 PM EDT

537.38

+2.21 (0.41%)

After-hours: Oct 22, 2026, 5:18 PM EDT

Vertex Pharmaceuticals Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Total Valuation

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Oct '26 Oct 22, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Market Capitalization	135,645	115,026	103,707	104,849	74,127	55,834
Market Cap Growth	26.24%	10.91%	-1.09%	41.44%	32.76%	-9.15%
Enterprise Value	123,981	104,851	94,253	91,965	65,181	49,750
Last Close Price	524.52	453.36	402.70	406.89	288.78	219.60

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Oct '26 Oct 22, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
PE Ratio	31.15	29.10	-	28.97	22.31	23.84
Forward PE	36.79	22.61	22.66	24.44	18.83	16.42
PS Ratio	10.77	9.58	9.41	10.62	8.30	7.37
PB Ratio	6.56	6.16	6.32	5.96	5.33	5.53
P/TBV Ratio	7.23	6.71	7.15	6.70	6.07	6.42
P/FCF Ratio	35.73	36.02	-	31.42	18.89	23.18
P/OCF Ratio	31.59	31.68	-	29.64	17.95	21.12
PEG Ratio	2.88	0.15	1.21	1.92	0.58	1.62

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Oct '26 Oct 22, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
EV/Sales Ratio	9.85	8.74	8.55	9.32	7.30	6.57
EV/EBITDA Ratio	24.30	21.55	20.59	20.54	14.40	12.38
EV/EBIT Ratio	25.25	22.37	21.45	21.35	14.89	12.78
EV/FCF Ratio	32.66	32.83	-	27.56	16.61	20.66

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Oct '26 Oct 22, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Debt / Equity Ratio	0.10	0.11	0.11	0.05	0.07	0.10
Debt / EBITDA Ratio	0.37	0.40	0.37	0.18	0.20	0.24
Debt / FCF Ratio	0.52	0.64	-	0.24	0.23	0.40
Net Debt / Equity Ratio	-0.58	-0.55	-0.58	-0.73	-0.72	-0.65
Net Debt / EBITDA Ratio	-2.29	-2.11	-2.07	-2.88	-2.21	-1.63
Net Debt / FCF Ratio	-3.07	-3.22	11.99	-3.87	-2.54	-2.72
Asset Turnover	0.49	0.50	0.49	0.48	0.57	0.60
Inventory Turnover	3.47	3.85	5.31	7.38	8.87	8.97
Quick Ratio	2.54	2.24	2.17	3.60	4.46	4.04
Current Ratio	3.19	2.90	2.69	3.99	4.83	4.46
Return on Equity (ROE)	23.54%	22.54%	-3.15%	22.99%	27.67%	24.93%
Return on Assets (ROA)	11.93%	12.16%	12.14%	13.17%	17.33%	19.32%
Return on Invested Capital (ROIC)	28.80%	30.54%	-98.60%	63.54%	90.72%	102.53%
Return on Capital Employed (ROCE)	20.90%	21.50%	23.20%	22.50%	28.40%	34.50%

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Oct '26 Oct 22, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Earnings Yield	3.21%	3.44%	-0.52%	3.45%	4.48%	4.20%
FCF Yield	2.80%	2.78%	-0.76%	3.18%	5.29%	4.31%
Buyback Yield / Dilution	0.85%	-0.04%	1.00%	-0.54%	0.31%	1.33%

SEC Filings: 10-K · 10-Q